Kathleen Gallagher
Corporate Officer/Principal en AVIDITY BIOSCIENCES, INC. .
Perfil
Kathleen Gallagher is currently the SVP & Global Head-Myotonic Dystrophy Type 1 at Avidity Biosciences, Inc. She previously worked as the Head-Communications at Merrimack Pharmaceuticals, Inc. from 2003 to 2016.
She also held the position of VP-Corporate Communications & Investor Relations at Akcea Therapeutics, Inc. Ms. Gallagher completed her undergraduate degree at Boston University.
Cargos activos de Kathleen Gallagher
| Empresas | Cargo | Inicio |
|---|---|---|
| AVIDITY BIOSCIENCES, INC. | Corporate Officer/Principal | - |
Antiguos cargos conocidos de Kathleen Gallagher.
| Empresas | Cargo | Fin |
|---|---|---|
| MERRIMACK PHARMACEUTICALS, INC. | Public Communications Contact | 01/10/2016 |
| AKCEA THERAPEUTICS, INC. | Contacto de Relaciones con Inversores | - |
Formación de Kathleen Gallagher.
| Boston University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| MERRIMACK PHARMACEUTICALS, INC. | Health Technology |
| AVIDITY BIOSCIENCES, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Kathleen Gallagher